|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9767
|
|
pubmed:dateCreated |
2011-2-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Systemic lupus erythematosus is a heterogeneous autoimmune disease that is associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-lymphocyte stimulator (BLyS). The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:BLISS-52 Study Group,
pubmed-author:FreimuthWilliamW,
pubmed-author:GallacherAlberto EAE,
pubmed-author:GuzmánRenato MRM,
pubmed-author:HallStephenS,
pubmed-author:JimenezRenato ERE,
pubmed-author:KimHo-YounHY,
pubmed-author:LanJoung-LiangJL,
pubmed-author:LeónManuel GMG,
pubmed-author:LevyRoger ARA,
pubmed-author:LiEdmund K-MEK,
pubmed-author:NasonovEugenyE,
pubmed-author:NavarraSandra VSV,
pubmed-author:PetriMichelle AMA,
pubmed-author:PinedaLiliaL,
pubmed-author:TanasescuComanC,
pubmed-author:ThomasMathewM,
pubmed-author:ZhongZ JohnZJ
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
26
|
|
pubmed:volume |
377
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
721-31
|
|
pubmed:dateRevised |
2011-6-20
|
|
pubmed:meshHeading |
pubmed-meshheading:21296403-Acute Disease,
pubmed-meshheading:21296403-Adult,
pubmed-meshheading:21296403-Aged,
pubmed-meshheading:21296403-Antibodies, Monoclonal,
pubmed-meshheading:21296403-Drug Administration Schedule,
pubmed-meshheading:21296403-Female,
pubmed-meshheading:21296403-Humans,
pubmed-meshheading:21296403-Immunologic Factors,
pubmed-meshheading:21296403-Logistic Models,
pubmed-meshheading:21296403-Lupus Erythematosus, Systemic,
pubmed-meshheading:21296403-Male,
pubmed-meshheading:21296403-Middle Aged,
pubmed-meshheading:21296403-Questionnaires,
pubmed-meshheading:21296403-Severity of Illness Index,
pubmed-meshheading:21296403-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
|
|
pubmed:affiliation |
University of Santo Tomas Hospital, Manila, Philippines.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
